peptide vaccine ipx
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2023 (NCT06094101)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06094101 | Phase 1/Phase 2 (Phase 2) | Sep 19, 2023 | Cooperative Weichteilsarkom Study Group, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cooperative Weichteilsarkom Study Group | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1